People: Actavis PLC (ACT)
14 Mar 2014
Mr. Sigurdur Oli Olafsson is President - Actavis Pharma, Director of the Company. He oversees global generics, specialty brands, branded generics, legacy brands, over-the-counter (OTC) and third-party commercial operations and business development. Mr. Olafsson joined Actavis (formerly known as Watson Pharmaceuticals, Inc. (“Watson”)) as Executive Vice President, Global Generics in September 2010, and was appointed President of the Global Generics business in April 2012. Prior to joining Actavis, Mr. Olafsson served as CEO of the Actavis Group from 2008 to 2010, where he was responsible for overseeing its global pharmaceutical business with operations in more than 40 countries. From 2006 to 2008, Mr. Olafsson served as Deputy CEO of the Actavis Group and, from 2003 to 2006, he was CEO, Actavis Inc. U.S. and Chief Executive Corporate Development. Prior to joining the Actavis Group, Mr. Olafsson held increasingly responsible positions with Pfizer’s Global Research and Development organization in both the U.S. and the UK from 1998 until 2003, and served as head of Drug Development for Omega Farma in Iceland for four years. Mr. Olafsson has a M.S. in Pharmacy (Cand Pharm) from the University of Iceland.
|Total Annual Compensation, USD||Long-Term Incentive Plans, USD||All Other, USD||Fiscal Year Total, USD|